Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report
J. J. Sternberg, R. B. Bracken, P. B. Handel and D. E. Johnson
Twelve patients with metastatic transitional cell carcinoma from the
urinary bladder were treated with a combination chemotherapy program
consisting of cisplatinum, cyclophosphamide, and doxorubicin hydrochloride
(CISCA). Ten patients had conditions for which a response to therapy could
be determined, and nine achieved an objective response (one complete
response, eight partial responses). Two additional patients with metastatic
transitional cell carcinoma from the renal pelvis were also treated, and
one achieved a partial response. In our experience, CISCA combination
chemotherapy has given the highest response rate of any protocol thus far
tested in advanced, metastatic urinary tract carcinoma.
